Successful nitrosamine compliance requires more than completing risk assessments—it requires integrating nitrosamine management into the existing Pharmaceutical Quality System (PQS). Zamann supports pharmaceutical companies in embedding nitrosamine and NDSRI processes into their quality systems, ensuring sustainable compliance with ICH M7, EMA, and FDA expectations throughout the product lifecycle.
We review existing quality processes, SOPs and governance structures to identify where nitrosamine requirements should be integrated. Our assessment evaluates current procedures against regulatory expectations and identifies opportunities to establish sustainable lifecycle management within the Pharmaceutical Quality System.
Zamann supports the integration of nitrosamine activities into existing quality processes, including risk assessment procedures, change control, supplier management, deviation management, CAPA, analytical testing, lifecycle reviews and document management. Standardized documentation ensures consistent execution and regulatory compliance across the organization.
We help establish governance structures, roles and esponsibilities to ensure long-term ownership of nitrosamine activities. Through practical implementation support and targeted training, organizations can integrate nitrosamine management into daily operations and maintain inspection-ready quality systems.
Our strategic approach to ensure Nitrosamine compliance is based on global and holistic experience, and can be perfectly adapted to your reality. We address the latest regulations and risk assessments, helping you manage and mitigate potential risks specific to your products and processes.
Zamann stays ahead of the evolving Nitrosamine requirements, providing expert guidance to ensure compliance with confidence. Our proactive and senior approach helps protect product integrity and patient safety, securing your operations against regulatory risks.
